Key result
A novel radioimmunoassay using digoxin 3'-hemisuccinate-BSA conjugate antiserum demonstrated high specificity for unmetabolized digoxin, measuring a mean concentration of 0.68 ng/ml in patient samples compared to 0.79-0.80 ng/ml with commercial antibodies.
Why the study?
Does a novel radioimmunoassay using digoxin 3'-hemisuccinate-BSA conjugate antiserum accurately measure serum digoxin in digitalized patients compared to commercial assays?
Population
35 serum samples from digitalized patients
Comparison
Radioimmunoassay using a novel anti-digoxin… vs Commercial antidigoxin BSA serum and monoclonal…
Design
Other
Authors
Loading...
May enhance digoxin assay specificity in practice; leaves open whether lower readings affect dosing or outcomes.
Does a novel radioimmunoassay using digoxin 3'-hemisuccinate-BSA conjugate antiserum accurately measure serum digoxin in digitalized patients compared to commercial assays?
Absolute Event Rate: 0.68% vs 0.79%
A novel radioimmunoassay for serum digoxin demonstrates sufficient precision for clinical use in digitalized patients.
Ikeda et al. (2002) studied Digitalized patients (n=35). Novel anti-digoxin antiserum (antibody A) vs. Commercial anti-digoxin BSA serum and monoclonal anti-digoxin was evaluated on Mean digoxin concentration (ng/ml). A novel radioimmunoassay using digoxin 3'-hemisuccinate-BSA conjugate antiserum demonstrated high specificity for unmetabolized digoxin, measuring a mean concentration of 0.68 ng/ml in patient samples compared to 0.79-0.80 ng/ml with commercial antibodies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: